Browse by author
Lookup NU author(s): Emerita Professor Sally Marshall
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Diabetic nephropathy is the leading cause of end stage renal disease worldwide and is associated with increased cardiovascular risk. The earliest clinical manifestation is of microalbuminuria. Tight blood glucose and blood pressure control reduce the risk of microalbuminuria. Once microalbuminuria is present, the rate of progression to end stage renal disease and of cardiovascular disease can be delayed by aggressive management of blood pressure, glucose, and lipids. Inhibition of the renin-angiotensin system is important to reduce intraglomerular pressure but other classes of antihypertensive agent may also be needed to gain adequate control of systemic blood pressure. Such measures can at least half the rate of progression of nephropathy and cardiovascular disease.
Author(s): Marshall SM
Publication type: Review
Publication status: Published
Journal: Postgraduate Medical Journal
ISSN (print): 0032-5473
ISSN (electronic): 1469-0756
PubMed id: 15537844